Pathogenesis and management of primary CNS lymphoma

References

• Gerstner ER, Batchelor TT. Primary central nervous system lymphoma. Arch. Neurol.67(3), 291–297 (2010).
   PubMedGoogle Scholar
• Flanagan EP, O’Neill BP, Porter AB, Lanzino G, Haberman TM, Keegan BM. Primary intramedullary spinal cord lymphoma. Neurology77(8), 784–791 (2011).
   PubMed Web of Science ®Google Scholar
• Schabet M. Epidemiology of primary CNS lymphoma. J. Neurooncol.43(3), 199–201 (1999).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Aguilar A, Soto-Hernandez JL. The management of primary central nervous system lymphoma related to AIDS in the HAART era. Curr. Opin. Oncol.23(6), 648–653 (2011).
   Google Scholar
• Mead GM, Bleehen NM, Gregor A et al. A Medical Research Council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer89(6), 1359–1370 (2000).
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Foppoli M et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised Phase 2 trial. Lancet374(9700), 1512–1520 (2009).
   PubMed Web of Science ®Google Scholar
• Thiel E, Korfel A, Martus P et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a Phase 3, randomised, non-inferiority trial. Lancet Oncol.11(11), 1036–1047 (2010).
   PubMed Web of Science ®Google Scholar
• Deckert-Schluter M, Rang A, Wiestler OD. Apoptosis and apoptosis-related gene products in primary non-Hodgkin’s lymphoma of the central nervous system. Acta Neuropathol.96(2), 157–162 (1998).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Shimada K, Ishida E, Konishi N. Histopathology, pathogenesis and molecular genetics in primary central nervous system lymphomas. Histol. Histopathol.19(1), 211–219 (2004).
   Google Scholar
• Bhagavathi S, Sharathkumar A, Hunter S et al. Activated B-cell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas. Clin. Neuropathol.27(1), 13–20 (2008).
   PubMed Web of Science ®Google Scholar
• Gualco G, Weiss LM, Barber GN, Bacchi CE. Diffuse large B-cell lymphoma involving the central nervous system. Int. J. Surg. Pathol.19(1), 44–50 (2011).
   Google Scholar
• Deckert M, Engert A, Bruck W et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia25(12), 1797–1807 (2011).
   PubMed Web of Science ®Google Scholar
• Jahnke K, Korfel A, O’Neill BP et al. International study on low-grade primary central nervous system lymphoma. Ann. Neurol.59(5), 755–762 (2006).
   PubMed Web of Science ®Google Scholar
• Lim T, Kim SJ, Kim K et al. Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes. Ann. Hematol.90(12), 1391–1398 (2011).
   Google Scholar
• Shenkier TN, Blay JY, O’Neill BP et al. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group. J. Clin. Oncol.23(10), 2233–2239 (2005).
   PubMed Web of Science ®Google Scholar
• Lossos IS, Alizadeh AA, Eisen MB et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc. Natl Acad. Sci. USA97(18), 10209–10213 (2000).
   PubMed Web of Science ®Google Scholar
• Montesinos-Rongen M, Van Roost D, Schaller C, Wiestler OD, Deckert M. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood103(5), 1869–1875 (2004).
   PubMed Web of Science ®Google Scholar
• Courts C, Montesinos-Rongen M, Martin-Subero JI et al. Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression. J. Neuropathol. Exp. Neurol.66(3), 230–237 (2007).
   PubMed Web of Science ®Google Scholar
• Montesinos-Rongen M, Schmitz R, Brunn A et al. Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma. Acta Neuropathol.120(4), 529–535 (2010).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Sakaki T, Hashimoto H et al. Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas. Cancer Res.61(17), 6335–6339 (2001).
   Google Scholar
• Harada K, Nishizaki T, Kubota H, Suzuki M, Sasaki K. Distinct primary central nervous system lymphoma defined by comparative genomic hybridization and laser scanning cytometry. Cancer Genet. Cytogenet.125(2), 147–150 (2001).
   Google Scholar
• Rubenstein JL, Fridlyand J, Shen A et al. Gene expression and angiotropism in primary CNS lymphoma. Blood107(9), 3716–3723 (2006).
   PubMed Web of Science ®Google Scholar
• Tun HW, Personett D, Baskerville KA et al. Pathway analysis of primary central nervous system lymphoma. Blood111(6), 3200–3210 (2008).
   PubMed Web of Science ®Google Scholar
• El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev.17(6), 463–474 (2006).
   PubMed Web of Science ®Google Scholar
• Riemersma SA, Jordanova ES, Schop RF et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood96(10), 3569–3577 (2000).
   PubMed Web of Science ®Google Scholar
• McCann KJ, Ashton-Key M, Smith K, Stevenson FK, Ottensmeier CH. Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development. Blood113(19), 4677–4680 (2009).
   PubMed Web of Science ®Google Scholar
• Riemersma SA, Oudejans JJ, Vonk MJ et al. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B-cell lymphomas of the brain and testis. J. Pathol.206(3), 328–336 (2005).
   PubMed Web of Science ®Google Scholar
• Courts C, Montesinos-Rongen M, Brunn A et al. Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma. J. Neuropathol. Exp. Neurol.67(7), 720–727 (2008).
   PubMed Web of Science ®Google Scholar
• Linnebank M, Schmidt S, Kolsch H et al. The methionine synthase polymorphism D919G alters susceptibility to primary central nervous system lymphoma. Br. J. Cancer90(10), 1969–1971 (2004).
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Dell’Oro S, Capello D et al. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br. J. Haematol.126(5), 657–664 (2004).
   PubMed Web of Science ®Google Scholar
• Kurzwelly D, Glas M, Roth P et al. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J. Neurooncol.97(3), 389–392 (2010).
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Matsuda K, Kitai R, Sato K, Kubota T. Angiogenesis in primary central nervous system lymphoma (PCNSL). J. Neurooncol.84(2), 141–145 (2007).
   PubMed Web of Science ®Google Scholar
• Cote TR, Manns A, Hardy CR, Yellin FJ, Hartge P. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J. Natl Cancer Inst.88(10), 675–679 (1996).
   PubMed Web of Science ®Google Scholar
• Mrugala MM, Rubenstein JL, Ponzoni M, Batchelor TT. Insights into the biology of primary central nervous system lymphoma. Curr. Oncol. Rep.11(1), 73–80 (2009).
   PubMedGoogle Scholar
• Chan CC, Rubenstein JL, Coupland SE et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist16(11), 1589–1599 (2011).
   PubMed Web of Science ®Google Scholar
• Buehring U, Herrlinger U, Krings T, Thiex R, Weller M, Kuker W. MRI features of primary central nervous system lymphomas at presentation. Neurology57(3), 393–396 (2001).
   Google Scholar
• Shibamoto Y, Ogino H, Suzuki G et al. Primary central nervous system lymphoma in Japan: changes in clinical features, treatment, and prognosis during 1985–2004. Neuro Oncol.10(4), 560–568 (2008).
   PubMed Web of Science ®Google Scholar
• Kawai N, Okubo S, Miyake K et al. Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings. Ann. Nucl. Med.24(5), 335–343 (2010).
   Google Scholar
• Kawase Y, Yamamoto Y, Kameyama R, Kawai N, Kudomi N, Nishiyama Y. Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma. Mol. Imaging Biol.13(6), 1284–1289 (2011).
   Google Scholar
• Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin’s lymphoma: a risk model. Ann. Oncol.13(7), 1099–1107 (2002).
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Zoldan MC, Terreni MR, Villa E. Importance of complete staging in non-Hodgkin’s lymphoma presenting as a cerebral mass lesion. Cancer77(5), 827–833 (1996).
   PubMed Web of Science ®Google Scholar
• Abrey LE, Batchelor TT, Ferreri AJ et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J. Clin. Oncol.23(22), 5034–5043 (2005).
   PubMed Web of Science ®Google Scholar
• Mohile NA, Deangelis LM, Abrey LE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol.10(2), 223–228 (2008).
   PubMed Web of Science ®Google Scholar
• Gonzales JA, Chan CC. Biopsy techniques and yields in diagnosing primary intraocular lymphoma. Int. Ophthalmol.27(4), 241–250 (2007).
   PubMedGoogle Scholar
• Merle-Beral H, Davi F, Cassoux N et al. Biological diagnosis of primary intraocular lymphoma. Br. J. Haematol.124(4), 469–473 (2004).
   PubMed Web of Science ®Google Scholar
• Schroers R, Baraniskin A, Heute C et al. Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology. Eur. J. Haematol.85(6), 520–528 (2010).
   PubMed Web of Science ®Google Scholar
• Fischer L, Martus P, Weller M et al. Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology71(14), 1102–1108 (2008).
   PubMed Web of Science ®Google Scholar
• Jahnke K, Hummel M, Korfel A et al. Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J. Clin. Oncol.24(29), 4754–4757 (2006).
   PubMed Web of Science ®Google Scholar
• Corry J, Smith JG, Wirth A, Quong G, Liew KH. Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int. J. Radiat. Oncol. Biol. Phys.41(3), 615–620 (1998).
   PubMed Web of Science ®Google Scholar
• Abrey LE, Ben-Porat L, Panageas KS et al. Primary central nervous system lymphoma: the Memorial Sloan–Kettering Cancer Center prognostic model. J. Clin. Oncol.24(36), 5711–5715 (2006).
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Blay JY, Reni M et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J. Clin. Oncol.21(2), 266–272 (2003).
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood103(1), 275–282 (2004).
   PubMed Web of Science ®Google Scholar
• Braaten KM, Betensky RA, de Leval L et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin. Cancer Res.9(3), 1063–1069 (2003).
   PubMed Web of Science ®Google Scholar
• Lin CH, Kuo KT, Chuang SS et al. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin. Cancer Res.12(4), 1152–1156 (2006).
   PubMed Web of Science ®Google Scholar
• Levy O, Deangelis LM, Filippa DA, Panageas KS, Abrey LE. BCL-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer112(1), 151–156 (2008).
   PubMed Web of Science ®Google Scholar
• Mathew BS, Carson KA, Grossman SA. Initial response to glucocorticoids. Cancer106(2), 383–387 (2006).
   Google Scholar
• Pels H, Juergens A, Schirgens I et al. Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma. Neuro Oncol.12(7), 720–724 (2010).
   PubMed Web of Science ®Google Scholar
• Bellinzona M, Roser F, Ostertag H, Gaab RM, Saini M. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur. J. Surg. Oncol.31(1), 100–105 (2005).
   PubMed Web of Science ®Google Scholar
• Porter AB, Giannini C, Kaufmann T et al. Primary central nervous system lymphoma can be histologically diagnosed after previous corticosteroid use: a pilot study to determine whether corticosteroids prevent the diagnosis of primary central nervous system lymphoma. Ann. Neurol.63(5), 662–667 (2008).
   PubMed Web of Science ®Google Scholar
• Roth P, Wick W, Weller M. Steroids in neurooncology: actions, indications, side-effects. Curr. Opin. Neurol.23(6), 597–602 (2010).
   PubMed Web of Science ®Google Scholar
• Nelson DF. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J. Neurooncol.43(3), 241–247 (1999).
   PubMed Web of Science ®Google Scholar
• Nelson DF, Martz KL, Bonner H et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int. J. Radiat. Oncol. Biol. Phys.23(1), 9–17 (1992).
   PubMed Web of Science ®Google Scholar
• Shibamoto Y, Ogino H, Hasegawa M et al. Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int. J. Radiat. Oncol. Biol. Phys.62(3), 809–813 (2005).
   PubMed Web of Science ®Google Scholar
• Correa DD, Shi W, Abrey LE et al. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol.14(1), 101–108 (2011).
   Google Scholar
• Blay JY, Bouhour D, Carrie C et al. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin’s lymphoma of patients with no known cause of immunosuppression. Blood86(8), 2922–2929 (1995).
   PubMed Web of Science ®Google Scholar
• Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J. Clin. Oncol.18(17), 3144–3150 (2000).
   PubMed Web of Science ®Google Scholar
• Bessell EM, Lopez-Guillermo A, Villa S et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J. Clin. Oncol.20(1), 231–236 (2002).
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J. Clin. Oncol.20(24), 4643–4648 (2002).
   PubMed Web of Science ®Google Scholar
• Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J. Clin. Oncol.21(24), 4483–4488 (2003).
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Dell’Oro S, Foppoli M et al. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology66(9), 1435–1438 (2006).
   PubMed Web of Science ®Google Scholar
• Shah GD, Yahalom J, Correa DD et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J. Clin. Oncol.25(30), 4730–4735 (2007).
   PubMed Web of Science ®Google Scholar
• Glass J, Shustik C, Hochberg FH, Cher L, Gruber ML. Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD). J. Neurooncol.30(3), 257–265 (1996).
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Guerra E, Regazzi M et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br. J. Cancer90(2), 353–358 (2004).
   PubMed Web of Science ®Google Scholar
• Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N. Engl. J. Med.293(4), 161–166 (1975).
   PubMed Web of Science ®Google Scholar
• Batchelor T, Carson K, O’Neill A et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J. Clin. Oncol.21(6), 1044–1049 (2003).
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Kuker W, Uhl M et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann. Neurol.57(6), 843–847 (2005).
   PubMed Web of Science ®Google Scholar
• Joerger M, Huitema AD, Krahenbuhl S et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trial. Br. J. Cancer102(4), 673–677 (2010).
   PubMed Web of Science ®Google Scholar
• Jahnke K, Korfel A, Martus P et al. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann. Oncol.16(3), 445–449 (2005).
   PubMed Web of Science ®Google Scholar
• Abrey LE. Advances in primary CNS lymphoma: randomized clinical trials of chemotherapy and whole-brain radiotherapy. Curr. Neurol. Neurosci. Rep.11(3), 243–245 (2011).
   Google Scholar
• Angelov L, Doolittle ND, Kraemer DF et al. Blood–brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J. Clin. Oncol.27(21), 3503–3509 (2009).
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Combs D, Rosenberg J et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood101(2), 466–468 (2003).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology76(10), 929–930 (2011).
   PubMed Web of Science ®Google Scholar
• Maza S, Kiewe P, Munz DL et al. First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neuro Oncol.11(4), 423–429 (2009).
   PubMed Web of Science ®Google Scholar
• Iwamoto FM, Schwartz J, Pandit-Taskar N et al. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer110(11), 2528–2534 (2007).
   PubMed Web of Science ®Google Scholar
• Voloschin AD, Betensky R, Wen PY, Hochberg F, Batchelor T. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J. Neurooncol.86(2), 211–215 (2008).
   PubMed Web of Science ®Google Scholar
• Fischer L, Thiel E, Klasen HA et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann. Oncol.17(7), 1141–1145 (2006).
   PubMed Web of Science ®Google Scholar
• Reni M, Zaja F, Mason W et al. Temozolomide as salvage treatment in primary brain lymphomas. Br. J. Cancer96(6), 864–867 (2007).
   PubMed Web of Science ®Google Scholar
• Pels H, Schmidt-Wolf IG, Glasmacher A et al. Primary central nervous system lymphoma: results of a pilot and Phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J. Clin. Oncol.21(24), 4489–4495 (2003).
   PubMed Web of Science ®Google Scholar
• Pels H, Juergens A, Glasmacher A et al. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a Phase II study. J. Neurooncol.91(3), 299–305 (2009).
   PubMed Web of Science ®Google Scholar
• Khan RB, Shi W, Thaler HT, DeAngelis LM, Abrey LE. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J. Neurooncol.58(2), 175–178 (2002).
   PubMed Web of Science ®Google Scholar
• Sierra Del Rio M, Ricard D, Houillier C et al. Prophylactic intrathecal chemotherapy in primary CNS lymphoma. J. Neurooncol.106(1), 143–146 (2012).
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Fridlyand J, Abrey L et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J. Clin. Oncol.25(11), 1350–1356 (2007).
   PubMed Web of Science ®Google Scholar
• Benesch M, Urban C. Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opin. Pharmacother.9(2), 301–309 (2008).
   PubMed Web of Science ®Google Scholar
• Ostermann K, Pels H, Kowoll A, Kuhnhenn J, Schlegel U. Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma. J. Neurooncol.103(3), 635–640 (2011).
   PubMed Web of Science ®Google Scholar
• Gallego Perez-Larraya J, Palma JA, Carmona-Iragui M et al. Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma. J. Neurooncol.103(3), 603–609 (2011).
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Glantz M, Schlegel U, Gisselbrecht C, Cavalli F. Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more. Semin. Oncol.36(4 Suppl. 2), S25–S34 (2009).
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Crocchiolo R, Assanelli A, Govi S, Reni M. High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leuk. Lymphoma49(11), 2042–2047 (2008).
   PubMed Web of Science ®Google Scholar
• Soussain C, Suzan F, Hoang-Xuan K et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J. Clin. Oncol.19(3), 742–749 (2001).
   PubMed Web of Science ®Google Scholar
• Soussain C, Hoang-Xuan K, Taillandier L et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J. Clin. Oncol.26(15), 2512–2518 (2008).
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Marks R, Ihorst G et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J. Clin. Oncol.24(24), 3865–3870 (2006).
   PubMed Web of Science ®Google Scholar
• Colombat P, Lemevel A, Bertrand P et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter Phase II study of the GOELAMS group. Bone Marrow Transplant.38(6), 417–420 (2006).
   PubMed Web of Science ®Google Scholar
• Kiefer T, Hirt C, Spath C et al. Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 Phase II study. Ann. Oncol. doi:10.1093/annonc/mdr553 (2011) (Epub ahead of print).
   Google Scholar
• Alimohamed N, Daly A, Owen C, Duggan P, Stewart DA. Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience. Leuk. Lymphoma doi:10.3109/10428194.2011.633250) (2011) (Epub ahead of print).
   Google Scholar
• Abrey LE, Moskowitz CH, Mason WP et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J. Clin. Oncol.21(22), 4151–4156 (2003).
   PubMed Web of Science ®Google Scholar
• Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology69(11), 1178–1182 (2007).
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J. Clin. Oncol.23(7), 1507–1513 (2005).
   PubMed Web of Science ®Google Scholar
• Plotkin SR, Betensky RA, Hochberg FH et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin. Cancer Res.10(17), 5643–5646 (2004).
   PubMed Web of Science ®Google Scholar
• Weller M, Platten M, Roth P, Wick W. Geriatric neuro-oncology: from mythology to biology. Curr. Opin. Neurol.24(6), 599–604 (2011).
   PubMed Web of Science ®Google Scholar
• Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br. J. Cancer105(9), 1414–1418 (2011).
   PubMed Web of Science ®Google Scholar
• Ng S, Rosenthal MA, Ashley D, Cher L. High-dose methotrexate for primary CNS lymphoma in the elderly. Neuro Oncol.2(1), 40–44 (2000).
   PubMed Web of Science ®Google Scholar
• Zhu JJ, Gerstner ER, Engler DA et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol.11(2), 211–215 (2009).
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, Taillandier L, Chinot O et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter Phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J. Clin. Oncol.21(14), 2726–2731 (2003).
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Marks R, Muller F et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and Phase II study. Ann. Oncol.20(2), 319–325 (2009).
   PubMed Web of Science ®Google Scholar
• Fritsch K, Kasenda B, Hader C et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann. Oncol.22(9), 2080–2085 (2011).
   PubMed Web of Science ®Google Scholar
• Omuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J. Neurooncol.85(2), 207–211 (2007).
   PubMed Web of Science ®Google Scholar
• Fliessbach K, Rogowski S, Hoppe C et al. Computer-based assessment of cognitive functions in brain tumor patients. J. Neurooncol.100(3), 427–437 (2010).
   PubMed Web of Science ®Google Scholar